Storia della carriera di Chuck Yon
Precedenti posizioni note di Chuck Yon
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| CHECKMATE PHARMACEUTICALS, INC. | Fondatore | 01/07/2015 | 04/01/2021 |
| Consigliere Generale | 01/07/2015 | 04/01/2021 | |
Coley Pharmaceutical Group, Inc.
 Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Consigliere Generale | 01/01/2001 | 01/01/2008 |
| Segretario Aziendale | 01/01/2001 | 01/01/2008 | |
| Astra Pharmaceutical Products, Inc. | Consigliere Generale | 01/01/1989 | 01/01/1999 |
Formazione di Chuck Yon
| Georgetown University Law Center | Graduate Degree |
| Kellogg School of Management | Masters Business Admin |
| Harvard College | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| General Counsel | 3 |
| Graduate Degree | 2 |
| Founder | 1 |
Settori
| Consumer Services | 4 |
| Health Technology | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
Coley Pharmaceutical Group, Inc.
Coley Pharmaceutical Group, Inc. Pharmaceuticals: MajorHealth Technology Coley Pharmaceutical Group, Inc. manufactures drugs to treat chronic diseases. The company discovers and develops receptors therapeutic candidates for cancers, asthma, and allergic disorders. It was founded in 1997 and is headquartered in Wellesley, MA | Health Technology |
| Astra Pharmaceutical Products, Inc. | |
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Chuck Yon
- Esperienza
